CO5261519A1 - Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos - Google Patents
Nuevos derivados de benzoimidazol utiles como agentes antiproliferativosInfo
- Publication number
- CO5261519A1 CO5261519A1 CO00091745A CO00091745A CO5261519A1 CO 5261519 A1 CO5261519 A1 CO 5261519A1 CO 00091745 A CO00091745 A CO 00091745A CO 00091745 A CO00091745 A CO 00091745A CO 5261519 A1 CO5261519 A1 CO 5261519A1
- Authority
- CO
- Colombia
- Prior art keywords
- amino
- alkyl
- carbonyl
- new
- derivatives useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Nuevos compuestos de acuerdo con la fórmula<EMI FILE="00091745_1" ID="1" IMF=JPEG >y sus sales farmacéuticamente aceptable, solvatos o hidratos, en que cada aparición de A se selecciona independiente entre CH ó N;X se selecciona entre el grupo que consta de -CH2-, -O-, -NH-, alquil (C1-C6)-amino, alquil (C1-C6)-amino-carbonil-amino, alquil (C1-C6)-carbonil-amino, alquil(C1-C6)-sulfonil-amino, fenil-sulfonil-amino, carbonilo, -NH-C(O)-, N-alquil (C1-C6)-C(O), S(O)y en que y es 0, 1 ó 2; y n es -(CH2)n- es 1, 2 ó 3; y R1, R2 y R3 son como se describen en esta memoria descriptiva; composiciones farmacéuticas que incluyen estos compuestos, y métodos para el tratamiento de una enfermedad auto-inmunitaria, una inflamación, una alergia, un rechazo de trasplante, y otras circunstancias en las que la administración de un agente supresor de inmunidad presenta un beneficio terapéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16822499P | 1999-11-30 | 1999-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5261519A1 true CO5261519A1 (es) | 2003-03-31 |
Family
ID=22610621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00091745A CO5261519A1 (es) | 1999-11-30 | 2000-11-30 | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1242403B1 (es) |
| JP (1) | JP3955468B2 (es) |
| KR (1) | KR20020059826A (es) |
| CN (1) | CN1402720A (es) |
| AP (1) | AP2002002530A0 (es) |
| AT (1) | ATE315036T1 (es) |
| AU (1) | AU1047601A (es) |
| BG (1) | BG106695A (es) |
| BR (1) | BR0015995A (es) |
| CA (1) | CA2392971C (es) |
| CO (1) | CO5261519A1 (es) |
| CZ (1) | CZ20021703A3 (es) |
| DE (1) | DE60025385T2 (es) |
| EA (1) | EA200200411A1 (es) |
| EE (1) | EE200200275A (es) |
| ES (1) | ES2253266T3 (es) |
| GT (1) | GT200000200A (es) |
| HN (1) | HN2000000264A (es) |
| HU (1) | HUP0203300A3 (es) |
| IL (1) | IL149103A0 (es) |
| IS (1) | IS6339A (es) |
| MA (1) | MA26846A1 (es) |
| MX (1) | MXPA02005350A (es) |
| NO (1) | NO20022557L (es) |
| OA (1) | OA12097A (es) |
| PA (1) | PA8506801A1 (es) |
| PE (1) | PE20010900A1 (es) |
| PL (1) | PL355946A1 (es) |
| SV (1) | SV2002000231A (es) |
| TN (1) | TNSN00232A1 (es) |
| TR (1) | TR200201431T2 (es) |
| UY (1) | UY26455A1 (es) |
| WO (1) | WO2001040215A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001237041B9 (en) * | 2000-02-17 | 2005-07-28 | Amgen Inc. | Kinase inhibitors |
| NZ523656A (en) * | 2000-08-31 | 2004-11-26 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1317450B1 (en) | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| CA2432222C (en) | 2000-12-21 | 2008-07-29 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| CN101037438A (zh) | 2002-08-02 | 2007-09-19 | 沃泰克斯药物股份有限公司 | 用作gsk－3的抑制剂的吡唑组合物 |
| DE10237423A1 (de) * | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen |
| US20040204458A1 (en) | 2002-08-16 | 2004-10-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of Lck inhibitors for treatment of immunologic diseases |
| RU2006129469A (ru) * | 2004-01-16 | 2008-02-27 | Новартис АГ (CH) | 2, 4-диаминопиримидины и их применение для индукции кардиомиогенеза |
| ATE512144T1 (de) * | 2004-10-12 | 2011-06-15 | Decode Genetics Ehf | Peri-substituierte bicyclische arylsulfonamide gegen arterielle verschlusskrankheiten |
| US20060161001A1 (en) * | 2004-12-20 | 2006-07-20 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| SG166827A1 (en) | 2005-11-03 | 2010-12-29 | Vertex Pharma | Aminopyrimidines useful as kinase inhibitors |
| US7622463B2 (en) | 2006-02-14 | 2009-11-24 | Vertex Pharmaceuticals Incorporated | Dihydrodiazepines useful as inhibitors of protein kinases |
| JP2009530288A (ja) * | 2006-03-16 | 2009-08-27 | ノバルティス アクチエンゲゼルシャフト | 特に黒色腫の処置のためのヘテロ環式有機化合物 |
| BRPI0811204A8 (pt) | 2007-05-10 | 2015-09-22 | Bristol Myers Squibb Co | Tetra-hidroibenzo-1,4-diazepinas substituídas por arila e heteroarila e uso das mesmas para bloquear a recaptação de norepinefrina, dopamina e serotonina |
| RU2464269C2 (ru) | 2007-10-16 | 2012-10-20 | Дайити Санкио Компани, Лимитед | Пиримидилиндолиновое соединение |
| ES2567280T3 (es) | 2009-09-25 | 2016-04-21 | Vertex Pharmaceuticals Incorporated | Métodos para preparar derivados de pirimidina útiles como inhibidores de proteína quinasa |
| EP2480553A2 (en) | 2009-09-25 | 2012-08-01 | Vertex Pharmaceuticals Incorporated | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors |
| TWI513694B (zh) * | 2010-05-11 | 2015-12-21 | Amgen Inc | 抑制間變性淋巴瘤激酶的嘧啶化合物 |
| KR101708761B1 (ko) * | 2012-04-13 | 2017-02-21 | 주식회사 머쉬메드 | 퓨린 유도체 또는 그의 염을 포함하는 아토피성 피부염의 예방 또는 치료용 조성물 |
| US10125144B2 (en) | 2013-10-07 | 2018-11-13 | Kadmon Corporation, Llc | Rho kinase inhibitors |
| EP3647311B1 (en) | 2017-06-30 | 2023-11-01 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof |
| CN110582491B (zh) | 2017-06-30 | 2023-09-29 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| JP2020525525A (ja) | 2017-06-30 | 2020-08-27 | ベイジン タイド ファーマシューティカル カンパニー リミテッドＢｅｉｊｉｎｇ Ｔｉｄｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | Ｒｈｏ−関連プロテインキナーゼ阻害剤、ｒｈｏ−関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| EP0837063A1 (en) * | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| GB9905075D0 (en) * | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
-
2000
- 2000-11-09 HU HU0203300A patent/HUP0203300A3/hu unknown
- 2000-11-09 AU AU10476/01A patent/AU1047601A/en not_active Abandoned
- 2000-11-09 CA CA002392971A patent/CA2392971C/en not_active Expired - Fee Related
- 2000-11-09 MX MXPA02005350A patent/MXPA02005350A/es active IP Right Grant
- 2000-11-09 EE EEP200200275A patent/EE200200275A/xx unknown
- 2000-11-09 CZ CZ20021703A patent/CZ20021703A3/cs unknown
- 2000-11-09 ES ES00971650T patent/ES2253266T3/es not_active Expired - Lifetime
- 2000-11-09 JP JP2001541899A patent/JP3955468B2/ja not_active Expired - Fee Related
- 2000-11-09 BR BR0015995-6A patent/BR0015995A/pt not_active Application Discontinuation
- 2000-11-09 CN CN00816506A patent/CN1402720A/zh active Pending
- 2000-11-09 EP EP00971650A patent/EP1242403B1/en not_active Expired - Lifetime
- 2000-11-09 PL PL00355946A patent/PL355946A1/xx not_active Application Discontinuation
- 2000-11-09 AT AT00971650T patent/ATE315036T1/de not_active IP Right Cessation
- 2000-11-09 TR TR2002/01431T patent/TR200201431T2/xx unknown
- 2000-11-09 DE DE60025385T patent/DE60025385T2/de not_active Expired - Lifetime
- 2000-11-09 AP APAP/P/2002/002530A patent/AP2002002530A0/en unknown
- 2000-11-09 OA OA1200200156A patent/OA12097A/en unknown
- 2000-11-09 IL IL14910300A patent/IL149103A0/xx unknown
- 2000-11-09 EA EA200200411A patent/EA200200411A1/ru unknown
- 2000-11-09 WO PCT/IB2000/001628 patent/WO2001040215A1/en not_active Ceased
- 2000-11-09 KR KR1020027006941A patent/KR20020059826A/ko not_active Ceased
- 2000-11-22 PA PA20008506801A patent/PA8506801A1/es unknown
- 2000-11-23 HN HN2000000264A patent/HN2000000264A/es unknown
- 2000-11-28 UY UY26455A patent/UY26455A1/es not_active Application Discontinuation
- 2000-11-28 PE PE2000001268A patent/PE20010900A1/es not_active Application Discontinuation
- 2000-11-29 GT GT200000200A patent/GT200000200A/es unknown
- 2000-11-29 TN TNTNSN00232A patent/TNSN00232A1/fr unknown
- 2000-11-29 SV SV2000000231A patent/SV2002000231A/es unknown
- 2000-11-30 CO CO00091745A patent/CO5261519A1/es unknown
-
2002
- 2002-04-12 IS IS6339A patent/IS6339A/is unknown
- 2002-05-13 BG BG106695A patent/BG106695A/bg unknown
- 2002-05-28 MA MA26655A patent/MA26846A1/fr unknown
- 2002-05-29 NO NO20022557A patent/NO20022557L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5261519A1 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| CO4290424A1 (es) | Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina | |
| AR023823A1 (es) | Compuestos derivados de piperazina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos. | |
| CY1107850T1 (el) | Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους | |
| CO5180642A1 (es) | Compuestos sustituidos de piperidina, procesos para su prepa racion, composiciones farmaceuticas que los contienen y su utilizacion | |
| ES2151083T3 (es) | Composiciones orales que contienen ondansetron. | |
| AR015649A1 (es) | Inhibidores de isoprenil-transferasas proteicas, composiciones que los comprenden y el uso de los mismos para la fabricacion de un medicamento | |
| CY1118191T1 (el) | Αναλογα δεοξυνοζιριμυκινης και οι χρησεις τους ως αναστολεις γλυκοζυλοκεραμιδασης | |
| GT199700095A (es) | Derivados 6,5-heterobiciclicos sustituidos. | |
| NO20013367L (no) | Colchinolderivater som vaskulorskadende midler | |
| ES2160648T3 (es) | Derivados de piridina. | |
| CL2004000174A1 (es) | Compuestos derivados de malonamida n,n'-disustituidos; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de la enfermedad de alzheimer. | |
| CO5251381A1 (es) | Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| ECSP941104A (es) | Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| PA8575401A1 (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso | |
| PA8529501A1 (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa -7." | |
| BR0313148A (pt) | Formulações de liberação controlada compreendendo lamotrigina | |
| CY1105198T1 (el) | Παραγωγα πιπepιδινης χρησιμα σαν ανταγωνιστες ccr5 για τη θepαπεια ιου ανθρωπινης ανοσοανεπαρκειας (hiv) | |
| CL2004000590A1 (es) | Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v | |
| CO5180578A1 (es) | Inhibidores de metaloproteasas dihetero substituida que son efectivos en el tratamiento de condiciones caracterizadas por la actividad excesiva de estas enzimas | |
| SV2002000235A (es) | Composiciones farmaceuticas que comprenden valdecoxib | |
| NO20052229L (no) | Basiske estere av fettalkoholer og deres anvendelse som antiinfammatoriske eller immunstimulerende midler | |
| AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
| UY27034A1 (es) | Derivados de pirimidina | |
| AR007052A1 (es) | Un derivado de carbohidrato, su uso y una composicion farmaceutica que lo comprende |